Research2d ago0 views

Lipopolysaccharide-Phospholipid Separation in the Outer Membrane Vesicle Model Promotes Preferential Binding of Antimicrobial Peptides at Lipid Interfaces.

LL-37 and other antimicrobial peptides just got a strategic map for attacking Gram-negative bacteria. Using molecular dynamics simulations, researchers from Shandong University and Monash University cracked open the mystery of how outer membrane vesicles (OMVs) in these bacteria organize their defenses — and where antimicrobial peptides find their weak spots.

P

J Chem Inf Model

by Mu K, Ma W, Ma Z et al.

Lipopolysaccharide-Phospholipid Separation in the Outer Membrane Vesicle Model Promotes Preferential Binding of Antimicrobial Peptides at Lipid Interfaces. Mu K(1)(2), Ma W(2), Ma Z(1), Ye J(3), Li J(2), Jiang X(1). Author information: (1)National Glycoengineering Research Center, Shandong University, Qingdao 266237, China. (2)Biomedicine Discovery Institute, Monash University, Melbourne 3800, Australia. (3)Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province 325000, China. Multidrug-resistant Gram-negative pathogens pose a major global medical challenge due to the lack of new antibiotics. Outer membrane vesicles (OMVs) in Gram-negative bacteria significantly contribute to their resistance to antimicrobial peptides (AMPs), particularly the lipopeptide polymyxins. However, how the structural organization of the OMV membranes influences AMP binding remains poorly understood. Here, we employed large-scale coarse-grained molecular dynamics simulations and enhanced sampling techniques to explore the structural dynamics of the OMV models and their interactions with polymyxins and other AMPs. Our results demonstrated that the separation of lipopolysaccharides (LPS) and phospholipids (PLs) occurred within the outer leaflet of the OMV models, forming LPS-rich regions, PL-rich regions, and LPS-PL interfaces. Interestingly, small geometric defects appeared at LPS-PL interfaces due to a mismatched orientation between LPS and PL molecules. These defects enhanced polymyxin binding to OMV models with folded conformations, in which their hydrophobic parts inserted into the PL-rich regions while the positively charged residues bound to the exposed phosphate groups of lipid A. Free energy calculations confirmed that polymyxins penetrated OMV models more effectively at LPS-PL interfaces than at LPS-rich regions. Importantly, this biased location at the LPS-PL interfaces was found across six other types of AMPs, including Melittin, LL-37, Magainin 2, Tachyplesin 1, Protegrin 1, and Capitellacin. Our findings suggest that the LPS-PL separation in the OMV models creates distinct microenvironments that favor AMP binding, particularly at LPS-PL interfaces. These mechanistic insights will inspire the design of novel AMPs that can evade the protective effect of the aforementioned OMVs.

Here’s the deal: OMVs aren’t just random blobs. Their outer membranes aren’t uniform. Instead, lipopolysaccharides (LPS) and phospholipids (PL) self-sort into distinct patches — LPS-rich, PL-rich, and interface zones where the two meet. These boundary zones aren’t smooth. They form geometric defects, basically micro-cracks at the LPS-PL interfaces.

Key takeaway: These microenvironments are peptide magnets. The simulations showed that LL-37, polymyxins, and five other research peptides zero in on these interfaces. They slip their hydrophobic segments into the PL-rich areas and use their positive charges to grab onto exposed phosphate groups. Free energy calculations showed these spots are easier to penetrate than the more uniform LPS-rich regions.

What does this mean for research?

If you’re screening or designing new antimicrobial peptides, aim for molecules that exploit these LPS-PL boundaries.

LL-37’s targeting is not a fluke — similar behavior was seen with Melittin, Magainin 2, Tachyplesin 1, Protegrin 1, and Capitellacin.

This opens up a new pathway for peptides to outmaneuver bacterial resistance shields.

Interested in LL-37’s binding dynamics or sourcing for your own work? Check out the ll-37 page or browse our vendor directory.

Bottom line: Targeting LPS-PL interfaces could be the next big move in antimicrobial peptide research. Now the field has the simulation data to back it up.

For Research Use Only

All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.